For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The Antisense and RNAi Therapeutics market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028.
This report elaborates the market size, market characteristics, and market growth of the Antisense and RNAi Therapeutics industry, and breaks down according to the type, application, and consumption area of Antisense and RNAi Therapeutics. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describes the leading companies.
In Chapter 2.3 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Antisense and RNAi Therapeutics in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
Chapter 2.5 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 6-10 consider the impact of COVID-19 on the regional economy.
Key players in the global Antisense and RNAi Therapeutics market covered in Chapter 11:
Alnylam Pharmaceuticals
Benitec Biopharma
Sanofi-Genzyme
GSK
Marina Biosciences
In Chapter 3, on the basis of types, the Antisense and RNAi Therapeutics market from 2018 to 2028 is primarily split into:
RNA Interference
Antisense RNA
In Chapter 4, on the basis of applications, the Antisense and RNAi Therapeutics market from 2018 to 2028 covers:
Oncology
Cardiovascular Diseases (CVDs)
Respiratory Disorders
Renal Diseases
Neurodegenerative Disorders
Genetic Disorders
Infectious Diseases
Other
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2028) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10:
North America (Covered in Chapter 6)
United States
Canada
Mexico
Europe (Covered in Chapter 7)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8)
China
Japan
South Korea
Australia
India
Middle East and Africa (Covered in Chapter 9)
Saudi Arabia
UAE
Egypt
South Africa
South America (Covered in Chapter 10)
Brazil
Argentina
Columbia
Years considered for this report:
Historical Years: 2018-2022
Base Year: 2022
Estimated Year: 2023
Forecast Period: 2023-2028